Patient Condition
MSA-C, progressive cerebellar ataxia for 14 months with orthostatic hypotension, constipation, and RBD. UMSARS-I 17, UMSARS-II 19, SCOPA-AUT 16. MRI showed middle cerebellar peduncle hyperintensity and pontine atrophy. Enrolled in IVIg therapy trial.
Treatment Timeline
| Phase | Details | Date |
|---|
| enrollment assessment | | |
| IVIg immunotherapy | | |
| follow-up assessments | | |
Treatment Outcome
| before | UMSARS-I points 17, UMSARS-II points 19, CSF NfL 68pg/mL, IL-6 increased |
|---|
| after | UMSARS-I improved to 15 points, UMSARS-II improved to 17 points, CSF NfL dropped to 50pg/mL (26% decrease), and IL-6 returned to normal levels |
|---|
| highlight | IVIg immunomodulatory treatment significantly improved motor function and neuroinflammatory indicators, and the return of IL-6 to normal suggests that the immune-mediated neuroprotective mechanism is effective |
|---|